文献速递MDS 与骨髓增殖性肿瘤白血病淋巴瘤

原发癌症患者诊断前意义未明克隆性造血与第二癌症风险

Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.
PubMed 文献 · Leukemia · 2026-04-14

该前瞻性队列研究纳入UK Biobank 2006至2022年间63690例首次诊断原发癌症的患者,分析诊断前CHIP与第二癌症风险的关系。中位随访3.9年,诊断前CHIP患者任何第二癌症风险升高(HR 1.3,95%CI 1.2-1.5),以第二髓系恶性肿瘤和非髓系血液恶性肿瘤风险尤为突出。

要点

  • 原发癌症患者中诊断前CHIP与任何第二癌症风险升高相关(HR 1.3,95%CI 1.2-1.5)。
  • 第二癌症超额风险以第二髓系恶性肿瘤和非髓系血液恶性肿瘤尤为明显。
  • 风险主要见于DNMT3A、TET2、SRSF2或JAK2突变型CHIP。

核心结论

  • 原发癌症患者诊断前存在CHIP与第二癌症风险升高相关,尤其第二髓系及非髓系血液恶性肿瘤。

研究设计与样本

  • 前瞻性队列研究,纳入UK Biobank 2006至2022年间63690例首次诊断原发癌症的患者。
  • 诊断前CHIP患者2860例,无诊断前CHIP患者60626例,采用Cox回归评估关联。

主要发现

  • 中位随访3.9年,诊断前CHIP患者任何第二癌症风险升高(HR 1.3,95%CI 1.2-1.5)。
  • 任何第二癌症风险升高主要见于原发骨髓增生异常肿瘤、骨髓增殖性肿瘤、非霍奇金淋巴瘤或乳腺癌且诊断前CHIP的患者。
  • 第二癌症超额风险以第二髓系恶性肿瘤和非髓系血液恶性肿瘤尤为高。
  • 第二癌症风险主要见于DNMT3A、TET2、SRSF2或JAK2突变型CHIP。

临床怎么用

  • 对原发癌症且诊断前存在CHIP的患者,应提高对第二癌症风险的警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an elevated risk of hematologic and solid cancers. We performed a prospective cohort study, including 63690 patients with a first diagnosis of primary cancer in the UK Biobank during 2006 to 2022, to investigate the association of pre-diagnostic CHIP with future risk of second cancers. Cox regression was employed to assess the association between pre-diagnostic CHIP and risk of developing second cancer among patients with primary cancer. We identified 2860 patients with and 60626 without pre-diagnostic CHIP. During a median follow-up of 3.9 years, patients with primary cancer with pre-diagnostic CHIP experienced a greater risk of any second cancer (hazard ratio 1.3, 95% confidence intervals 1.2-1.5), compared with those without pre-diagnostic CHIP. Increased risk of any second cancer was mainly noted for patients with pre-diagnostic CHIP and primary myelodysplastic neoplasia, myeloproliferative neoplasms, non-Hodgkin lymphoma, or breast cancer. Regarding types of outcome (i.e., second cancer), the excess risk was particularly high for second myeloid malignancy and non-myeloid hematological malignancy. The risk for a second cancer was mainly observed in DNMT3A-, TET2-, SRSF2-, or JAK2-mutant CHIP. These findings suggest increased awareness of second cancer risk among patients with primary cancer and pre-diagnostic CHIP.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Liu X, Adami HO, Boberg E, et al. Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers. Leukemia. 2026. PMID: 41981103. doi:10.1038/s41375-026-02946-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。